

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 3298.1003-000	APPLICATION NO. 10/087,996
INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION			FIRST NAMED INVENTOR Brian Leyland-Jones	FILING DATE February 28, 2002
March 22, 2004 (Use several sheets if necessary)			EXAMINER Not yet assigned	CONFIRMATION NO. 2676
				GROUP 1641

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
RL	AA	5,830,672	11-03-1998	Wainer <i>et al.</i>

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
RL	AL	WO 00/55624 A2	09-21-2000	Brian Leyland-Jones	
/	AM	WO 95/04757 A1	02-16-1995	Board of Regents, University of Texas System	

OTHER DOCUMENTS (*Including Author, Title, Date, Pertinent Pages, Etc.*)

RL	AR	Wong, P.N., <i>et al.</i> "Syntheses of Caffeine Metabolites Derivatives for Measuring CYP1A2 Activity by ELISA," <i>Proceedings of the 90th Annual Meeting of the American Association for Cancer Research</i> , 40:53 (1999).
/	AS	Iyer, L. and Ratain, M.J., "Pharmacogenetics and Cancer Chemotherapy," <i>European Journal of Cancer</i> , 34(10):1493-1499 (1998).
/	AT	Innocenti, F., <i>et al.</i> "Pharmacogenetics of Anticancer Agents: Lessons for Amonafide and Irinotecan," <i>Drug Metabolism and Disposition</i> , 29(4 part 2): 596-600 (2001).

EXAMINER <i>Amy A. Lewis</i>	DATE CONSIDERED 11/29/04
---------------------------------	-----------------------------

PTO-1449 REPRODUCED	ATTORNEY DOCKET NO. 3298.1003-000	APPLICATION NO. 10/087,996
O I P INFORMATION DISCLOSURE CITATION IN AN APPLICATION <i>AUG 09 2004</i> Use several sheets if necessary)	FIRST NAMED INVENTOR Brian Leyland-Jones	FILING DATE February 28, 2002
	EXAMINER Not yet assigned	CONFIRMATION NO. 2676
		GROUP 1641

EXAMINER *Aug A Lewis*

DATE CONSIDERED

11/29/04

PTO-1449 REPRODUCED O I P E INFORMATION DISCLOSURE CITATION IN AN APPLICATION AUG 09 2004 SEARCHED SERIALIZED INDEXED FILED August 5, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 3298.1003-000	APPLICATION NO. 10/087,996
	FIRST NAMED INVENTOR Brian Leyland-Jones	FILING DATE February 28, 2002
	EXAMINER Not yet assigned	CONFIRMATION NO. 2676
		GROUP 1641

FOREIGN PATENT DOCUMENTS

EXAMINER

NER *Angey A. His*
1. NORMAL AND ABNORMAL THERAPY IN
1957-1958

DATE CONSIDERED

11/29/04

PTO-1449 REPRODUCED D I P E AUG 09 2004 PATENT TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTORNEY DOCKET NO. 3298.1003-000	APPLICATION NO. 10/087,996
August 5, 2004 (Use several sheets if necessary)		FIRST NAMED INVENTOR Brian Leyland-Jones	FILING DATE February 28, 2002
		EXAMINER Not yet assigned	CONFIRMATION NO. 2676
			GROUP 1641

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RQ	AU	Beste, G., et al., "Small Antibody-Like Proteins with Prescribed Ligand Specificities Derived from the Lipocalin Fold," <i>Proc. Natl. Sci.</i> , 96:1898-1903 (1999).	
	AV	Rabbany, S. Y., et al., "Optical Immunosensors," <i>Crit. Rev. Biomed. Eng.</i> , 22(5/6):307-346 (1994).	
	AW	Wang, J., et al., "Mismatch-Sensitive Hybridization Detection by Peptide Nucleic Acids Immobilized on a Quartz Crystal Microbalance," <i>Anal. Chem.</i> , 69(24):5200-5202 (1997).	
	AX	Wong, P., et al., "A Competitive Enzyme Linked Immunosorbent Assay for the Determination of N-acetyltransferase (NAT2) Phenotypes," <i>J. Pharm. Biomed. Anal.</i> , 13:1079-1086 (1995).	
	AY	Desta, Z., et al., "Effect of Clarithromycin on the Pharmacokinetics and Pharmacodynamics of Pimozide in Healthy Poor and Extensive Metabolizers of Cytochrome P450 2D6 (CYP2D6)," <i>Clin. Pharmacol. Ther.</i> , 65(1):10-20 (1999).	
	AZ	Tang, B. K., et al., "Caffeine as a Metabolic Probe: Validation of its Use for Acetylator Phenotyping," <i>Clin. Pharmacol. Ther.</i> , 49(6):648-657 (1991).	
	AR2	Wolf, C. R., et al., "Chapter 18. Cytochrome P450 CYP2D6," <i>Metabolic Polymorphisms and Susceptibility to Cancer</i> , 148:209-229 (1999).	
	AS2	Kroemer, H. K., et al., "Molecular Bases and Clinical Consequences of Genetic Cytochrome P450 2D6 Polymorphism," <i>Life Sci.</i> , 56(26):2285-2298 (1995).	
	AT2	Kenworthy, K. E., et al., "CYP3A4 Drug Interactions: Correlation of 10 <i>In Vitro</i> Probe Substrates," <i>Br. J. Clin. Pharmacol.</i> , 48:716-727 (1999).	
	AU2	Hirth, J., et al., "The Effect of an Individual's Cytochrome CYP3A4 Activity on Docetaxel Clearance," <i>Clin. Cancer Res.</i> , 6:1255-1258 (2000).	
	AV2	Thummel, K. E., et al., " <i>In Vitro</i> and <i>In Vivo</i> Drug Interactions Involving Human CYP3A," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 38:389-430 (1998).	

EXAMINER 	DATE CONSIDERED 11/29/04
---	-----------------------------